Abnormalities of motor function, transcription and cerebellar structure in mouse models of THAP1 dystonia.

DYT6 dystonia is caused by mutations in THAP1 [Thanatos-associated (THAP) domain-containing apoptosis-associated protein] and is autosomal dominant and partially penetrant. Like other genetic primary dystonias, DYT6 patients have no characteristic neuropathology, and mechanisms by which mutations in THAP1 cause dystonia are unknown. Thap1 is a zinc-finger transcription factor, and most pathogenic THAP1 mutations are missense and are located in the DNA-binding domain. There are also nonsense mutations, which act as the equivalent of a null allele because they result in the generation of small mRNA species that are likely rapidly degraded via nonsense-mediated decay. The function of Thap1 in neurons is unknown, but there is a unique, neuronal 50-kDa Thap1 species, and Thap1 levels are auto-regulated on the mRNA level. Herein, we present the first characterization of two mouse models of DYT6, including a pathogenic knockin mutation, C54Y and a null mutation. Alterations in motor behaviors, transcription and brain structure are demonstrated. The projection neurons of the deep cerebellar nuclei are especially altered. Abnormalities vary according to genotype, sex, age and/or brain region, but importantly, overlap with those of other dystonia mouse models. These data highlight the similarities and differences in age- and cell-specific effects of a Thap1 mutation, indicating that the pathophysiology of THAP1 mutations should be assayed at multiple ages and neuronal types and support the notion of final common pathways in the pathophysiology of dystonia arising from disparate mutations.

[1]  K. Lohmann,et al.  THAP1, the gene mutated in DYT6 dystonia, autoregulates its own expression. , 2014, Biochimica et biophysica acta.

[2]  A. Richter,et al.  Genetic animal models of dystonia: Common features and diversities , 2014, Progress in Neurobiology.

[3]  M. Ehrlich,et al.  Dystonia type 6 gene product Thap1: identification of a 50 kDa DNA-binding species in neuronal nuclear fractions , 2014, Acta neuropathologica communications.

[4]  W. Dauer,et al.  TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration. , 2014, The Journal of clinical investigation.

[5]  A. Blitzer,et al.  A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia , 2014, Molecular genetics & genomic medicine.

[6]  H. Jinnah,et al.  Subtle microstructural changes of the cerebellum in a knock-in mouse model of DYT1 dystonia , 2014, Neurobiology of Disease.

[7]  H. Steiner,et al.  Behavioral and transcriptome alterations in male and female mice with postnatal deletion of TrkB in dorsal striatal medium spiny neurons , 2013, Molecular Neurodegeneration.

[8]  A. Pisani,et al.  New genetic insights highlight ‘old’ ideas on motor dysfunction in dystonia , 2013, Trends in Neurosciences.

[9]  M. LeDoux,et al.  Emerging common molecular pathways for primary dystonia , 2013, Movement disorders : official journal of the Movement Disorder Society.

[10]  S. Campagne,et al.  NMR studies of a new family of DNA binding proteins: the THAP proteins , 2013, Journal of biomolecular NMR.

[11]  S. Mcconnell,et al.  A network of genetic repression and derepression specifies projection fates in the developing neocortex , 2012, Proceedings of the National Academy of Sciences.

[12]  H. Jinnah,et al.  Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia , 2012, Neurobiology of Disease.

[13]  L. Ozelius,et al.  Dimerization of the DYT6 dystonia protein, THAP1, requires residues within the coiled‐coil domain , 2011, Journal of neurochemistry.

[14]  C. Barnum,et al.  Behavioral and Cellular Modulation of l-DOPA-Induced Dyskinesia by β-Adrenoceptor Blockade in the 6-Hydroxydopamine-Lesioned Rat , 2011, Journal of Pharmacology and Experimental Therapeutics.

[15]  D. Eidelberg,et al.  Hereditary dystonia as a neurodevelopmental circuit disorder: Evidence from neuroimaging , 2011, Neurobiology of Disease.

[16]  S. Lehéricy,et al.  The functional neuroanatomy of dystonia , 2011, Neurobiology of Disease.

[17]  S. Schneider,et al.  Homozygous THAP1 mutations as cause of early‐onset generalized dystonia , 2011, Movement disorders : official journal of the Movement Disorder Society.

[18]  K. Hashimoto,et al.  Altered Dendritic Morphology of Purkinje cells in Dyt1 ΔGAG Knock-In and Purkinje Cell-Specific Dyt1 Conditional Knockout Mice , 2011, PloS one.

[19]  John Meitzen,et al.  β1‐Adrenergic receptors activate two distinct signaling pathways in striatal neurons , 2011, Journal of neurochemistry.

[20]  Rogely Waite Boyce,et al.  Design-based Stereology , 2010, Toxicologic pathology.

[21]  M. Ehrlich,et al.  Direct interaction between causative genes of DYT1 and DYT6 primary dystonia , 2010, Annals of neurology.

[22]  K. Lohmann,et al.  The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6) , 2010, Annals of neurology.

[23]  M. Rice,et al.  Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (ΔE) TorsinA in transgenic mice , 2010, Neurobiology of Disease.

[24]  J. Berger,et al.  THAP proteins target specific DNA sites through bipartite recognition of adjacent major and minor grooves , 2009, Nature Structural &Molecular Biology.

[25]  D. Leroith,et al.  High-Efficient FLPo Deleter Mice in C57BL/6J Background , 2009, PloS one.

[26]  D. Tao,et al.  Neural cell cycle dysregulation and central nervous system diseases , 2009, Progress in Neurobiology.

[27]  S. Bressman,et al.  Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia , 2009, Nature Genetics.

[28]  M. Ehrlich,et al.  Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. , 2008, Human molecular genetics.

[29]  T. Wichmann Commentary: Dopaminergic dysfunction in DYT1 dystonia , 2008, Experimental Neurology.

[30]  X. Breakefield,et al.  Dopamine release is impaired in a mouse model of DYT1 dystonia , 2007, Journal of neurochemistry.

[31]  M. Hallett,et al.  Do primary adult-onset focal dystonias share aetiological factors? , 2007, Brain : a journal of neurology.

[32]  C. Mathé,et al.  The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. , 2007, Blood.

[33]  M. Chesselet,et al.  Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism , 2006, Behavioural pharmacology.

[34]  A. Bentivoglio,et al.  Non‐DYT1 early‐onset primary torsion dystonia: Comparison with DYT1 phenotype and review of the literature , 2006, Movement disorders : official journal of the Movement Disorder Society.

[35]  C. Englund,et al.  Development of the Deep Cerebellar Nuclei: Transcription Factors and Cell Migration from the Rhombic Lip , 2006, The Journal of Neuroscience.

[36]  P. R. Hof,et al.  Design-based stereology in neuroscience , 2005, Neuroscience.

[37]  J. Girault,et al.  cAMP and Extracellular Signal-Regulated Kinase Signaling in Response to d-Amphetamine and Methylphenidate in the Prefrontal Cortex in Vivo: Role of β1-Adrenoceptors , 2005, Molecular Pharmacology.

[38]  C. Mathé,et al.  The THAP domain of THAP1 is a large C2CH module with zinc-dependent sequence-specific DNA-binding activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Baker,et al.  mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Schmidt,et al.  Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6‐hydroxydopamine‐induced partial degeneration of substantia nigra in rats , 2003, The European journal of neuroscience.

[41]  Sophia Kossida,et al.  The THAP domain: a novel protein motif with similarity to the DNA-binding domain of P element transposase. , 2003, Trends in biochemical sciences.

[42]  P. Thier,et al.  Quantitative organization of neurotransmitters in the deep cerebellar nuclei of the Lurcher mutant , 2002, The Journal of comparative neurology.

[43]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[44]  R. Spang,et al.  Role for E2F in Control of Both DNA Replication and Mitotic Functions as Revealed from DNA Microarray Analysis , 2001, Molecular and Cellular Biology.

[45]  K. L. Tucker Methylated Cytosine and the Brain A New Base for Neuroscience , 2001, Neuron.

[46]  Yusu Gu,et al.  A Post-transcriptional Compensatory Pathway in Heterozygous Ventricular Myosin Light Chain 2-Deficient Mice Results in Lack of Gene Dosage Effect during Normal Cardiac Growth or Hypertrophy* , 1999, The Journal of Biological Chemistry.

[47]  T. Hökfelt,et al.  The distribution and significance of CNS adrenoceptors examined with in situ hybridization. , 1996, Trends in pharmacological sciences.

[48]  Emma Carrick,et al.  Dopa‐responsive dystonia , 1994, Annals of neurology.

[49]  R. Solaro,et al.  Molecular and physiological effects of alpha-tropomyosin ablation in the mouse. , 1998, Circulation research.

[50]  K. Rajewsky,et al.  A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. , 1995, Nucleic acids research.

[51]  K. Mizukawa,et al.  MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. , 1987, European neurology.